Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
OptiNose AS announced that its Phase III ReOpen1 clinical trial met both of its co-primary endpoints. It will be used to treat patients diagnosed with chronic sinusitis.
As state and local governments across the United States begin to lift mitigation efforts, the death toll continues to climb across the globe, a reminder that COVID-19 is still a serious public health concern.
BMS and Opdivo’s blockbuster checkpoint inhibitor picked up a new regulatory win after the FDA approved the cancer drug in combination with platinum-doublet chemotherapy.
China has become a leader in biotech in the last five years, especially in CAR-T therapies. Companies like Johnson & Johnson are on the prowl to acquire Chinese companies to form collaborations.
Shares of bluebird bio were falling rapidly in premarket trading Monday morning after the company revealed its dire financial straits over the weekend.
Three biotech firms announced a change in leadership recently, led by Pardes Biosciences, followed by HUTCHMED and BeiGene. Read the details below.
The Phase I study could potentially result in RP-A501 becoming the first gene therapy for monogenic heart failure.
Robert Califf became the new commissioner of the U.S. Food & Drug Administration and emphasized the use of real-world evidence (RWE) in Agency decisions.
With all of this innovation coming down the pike, Gallant shared that Daiichi Sankyo is currently in growth mode, particularly when it comes to oncology.
Several cases of Japanese encephalitis have been confirmed in Australia and may have spread from pigs to humans, although it can also spread from horses.
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
Although at-home testing for COVID-19 has been dismal, the revolution in at-home testing has inspired personal tests for several other illnesses.
PRESS RELEASES
• ASCO 2026: 2.5-Year Overall Survival Data • Jefferies Healthcare Conference: Partnering & Investor meetings • BIO International Convention: Panel Participation • MIB Agents Factor Osteosarcoma Conference: Data Presentation
The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia’s Authorised Prescriber Scheme, where no serious adverse events have been reported as of December 2025
Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDT
• MustGrow has received approval from the agriculture departments of Texas, Utah, and Montana to commence sales of organic biofertility product TerraSanteTM. • Based on infield grower data, the mustard-derived TerraSanteTM biofertility product has been shown to improve crop yields, soil, and potentially the soil microbiome health for nutrient/water use efficiencies.
· Prof. Dr. med. Jürgen Braun joins the Scientific Advisory Board of MetrioPharm AG. · With more than 800 peer-reviewed publications and various prestigious awards, Prof. Braun is internationally recognized as a leading expert in the field of modern clinical and academic rheumatology.
Pharmaceutical service provider receives prestigious management award for the seventh year in a row · Family-owned company once again excels in all four key business areas · Site development and digitalization as strategic investment priorities · Focus on new sources for skilled workers and on lifelong learning
The upgraded platform offers a searchable database of over 300 risk-assessed HCPs, automated research scanning, and new flexible pricing options for mid-size drug developers.
New preprint by Jianghui Xiong, PhD, and the DeepoMe team introduces SteeraMed, a steerable biomedical world model for N-of-1 intervention reasoning across chronic diseases and aging